COSMIC-19 study (COntinuous Signs Monitoring in Covid-19 patients)
Press Release – August 13, 2020
Alderley Park-based Aptus Clinical Ltd today announced that recruitment has started on the innovative COSMIC-19 study, which they believe will help transform and shape clinical trial monitoring in the future.
COSMIC-19 study (COntinuous Signs Monitoring in Covid-19 patients), sponsored by The Christie NHS Foundation Trust in collaboration with Manchester University Foundation NHS Trust, utilises advanced Artificial Intelligence (AI) capabilities provided by Zenzium. Aptus Clinical are providing specialist Data Management and Clinical Operations support, enabling compliant data handling and aggregation infrastructure.
The COSMIC-19 pilot study aims to recruit 60 inpatients who are suspected or confirmed as having COVID-19. Each patient will have vital signs and observations monitored using advanced wireless wearable sensors, with Zenzium’s proprietary AI technology used to retrospectively look for predictive patterns in the patients’ vital signs which could be used to alert the medical team if the patient is deteriorating. If the prediction indicates that the patient needs critical care, the medical team could then potentially intervene earlier giving patients the best chance of recovery.
Steve McConchie, CEO of Aptus Clinical said: “We are delighted to have provided clinical operations support for this important and transformative clinical trial. Working with the NHS and AI partners, we have developed a novel data sharing system that compliantly integrates biosensor data from patients with their clinical data and transfers it seamlessly to Zenzium for analysis. We are confident that the infrastructure we have built in Manchester can be easily applied to ensure future clinical trials benefit from these AI driven insights, and ultimately lead to better therapies for patients.”
Anthony D. Bashall, Managing Director & Founder of Zenzium stated, “We are extremely excited to apply our AI technology based on time-series Deep Learning including DeepHRV® to this challenge, with the potential to make a substantial impact on patient outcomes.”
The COSMIC-19 Principal Investigator, Professor Fiona Thistlethwaite, medical oncologist at The Christie, said, “Unfortunately some patients who are suffering from COVID-19 on our hospital wards can become seriously unwell. By using this system, we hope to be able to identify these patients early and this may mean we can optimise their management without the need for them to go to intensive care.”
Dr Anthony Wilson, the Intensive Care Consultant coordinating the trial at MFT, said, “This technology is a glimpse of how we will monitor hospital patients in the future and it’s fantastic that MFT and The Christie are frontrunners in such innovation.”
About Aptus Clinical
Aptus Clinical Limited is a full-service clinical contract research organisation specialising in the design, conduct and delivery of early phase clinical studies with a particular focus in oncology, rare diseases, cell and gene therapies. Projects are delivered by a team of highly experienced drug development scientists with a track record of successfully delivering clinical development programmes, including some of the leading pharmaceutical brands. Aptus Clinical partners with clients to help them transform their promising projects into valued therapies.
For more information, visit www.aptusclinical.com or call on +44 (0) 1625 238662
Zenzium is an end-to-end solution provider focused on applying its ground-breaking Artificial Intelligence (AI) technology within healthcare for the management of a number of severe diseases both acute and chronic. Zenzium’s core technology, including DeepHRV®, is based on Deep Learning as applied to time-series measurements and data. Zenzium was founded in 2016 and is headquartered at Alderley Park in Macclesfield, Cheshire, UK.
Additional information is available at www.zenzium.com or on +44 (0) 1625 725970
DeepHRV® is a Registered Trademark of Zenzium, Ltd.
About The Christie
The Christie opened in 1901 and is now one of Europe’s leading cancer centres and the largest single-site centre in Europe
The Christie is one of Europe's experimental cancer medicine centres and an international leader in research and development with around 650 clinical studies ongoing at any one time. The NIHR Manchester Clinical Research Facility at The Christie provides a high quality, dedicated clinical research environment for our patients to participate in trials.
Visit www.christie.nhs.uk to find out more or find us on social media @TheChristieNHS
About Manchester Foundation HNS Trust
Manchester University NHS Foundation Trust is one of the largest NHS Trusts in the country and a leading provider of specialist healthcare services. Its nine hospitals are home to hundreds of world class clinicians and academic staff committed to finding patients the best care and treatments.
Its hospitals are Manchester Royal Infirmary, Saint Mary's Hospital, Royal Manchester Children's Hospital, Manchester Royal Eye Hospital, University Dental Hospital of Manchester, Trafford General, Altrincham Hospital, Wythenshawe Hospital and Withington Hospital.
From 1st April, 2020 a tenth hospital - North Manchester General Hospital - has taken the first step in joining the MFT group through a Management Agreement.
More information is available at www.mft.nhs.uk